Bob advised pharmaceutical, biotech and software clients in high-stakes matters, including mission-critical patent procurement, transactional matters, due diligence, inter partes review, district court cases and Federal Circuit appeals. His work included complex software patents and development agreements, patent portfolios for Orange Book drugs, ANDA litigations, biotech patent cases, and international disputes. A common thread throughout his work was integrity – in both senses: genuine sincerity and determined coherence.

Bob’s work in biotech and pharmaceuticals related to small-molecule drugs, biologic therapies, vaccines and formulation design, particularly for pain management; neurological, autoimmune and cardiac disorders; antivirals; antibiotics; cancer; HIV; malaria; and diabetes. He worked extensively in directed evolution of genes and proteins, combinatorial chemistry, rational drug design, nanotechnology, microfluidic devices, genomics and proteomics, genetically engineered antigens and antibodies, therapeutic and industrial enzymes, personalized medicine, and bioinformatics.

For software clients, Bob advised with respect to financial transaction software, digital rights management, streaming and data compression technologies, content delivery, distributed networking, caching and memory management, security and encryption, network diagnostics, software certificates, digital watermarking, antivirus software, document management software, and graphical user interfaces.